埃兹蛋白在皮肤鳞状细胞癌、基底细胞上皮瘤、脂溢性角化病中的表达及临床意义

目的 探讨埃兹蛋白（ezrin）在脂溢性角化病、基底细胞上皮瘤、皮肤鳞状细胞癌中的表达及其与临床病理参数之间的相关性。方法 采用免疫组化法（SP法）检测36例皮肤鳞状细胞癌、27例基底细胞上皮瘤和20例脂溢性角化病、10例正常人皮肤中埃兹蛋白表达水平。结果 埃兹蛋白在正常人皮肤、脂溢性角化病、基底细胞上皮瘤、皮肤鳞状细胞癌中的阳性率分别为20.0%,25.0%,66.7％和91.3%,除脂溢性角化病组外,各肿瘤组与正常人对照组比较,阳性率差异均有统计学意义（H = 40.061,P < 0.01）。埃兹蛋白表达水平与皮肤肿瘤良恶性、与皮肤鳞状细胞癌的病理分级及肿瘤有无淋巴结转移均呈正相关（r分别为0.87,0.80,0.89）。COX回归显示,埃兹蛋白表达水平是皮肤鳞状细胞癌预后的独立影响因素之一。结论 脂溢性角化病、基底细胞上皮瘤、皮肤鳞状细胞癌组织中埃兹蛋白阳性表达水平与皮肤肿瘤的良恶性、皮肤鳞状细胞癌病理分级及有无淋巴结转移有关。     

iNOS在皮肤肿瘤中的表达及其意义

目的:检测诱导型一氧化氮合酶(iNOS)在皮肤良恶性肿瘤中的表达。方法:采用免疫组织化学技术检测25例脂溢性角化病、25例光线性角化病、25例基底细胞癌、30例鳞状细胞癌(I级13例,II-III级17例)、10例正常皮肤组织中iNOS的表达。结果:2例(8.00%)脂溢性角化病、13例(52.00%)光线性角化病、11例(44.00%)基底细胞癌、22例(73.33%)鳞状细胞癌中iNOS呈阳性表达,正常皮肤表达均为阴性。iNOS在鳞状细胞癌、基底细胞癌及光线性角化病中的阳性率明显高于脂溢性角化病组(P<0.01),鳞状细胞癌组与光线性角化病组间无明显差别(P>0.05),与其他各组间差异显著(P<0.01或P<0.05),II III级鳞状细胞癌iNOS表达明显高于I级鳞状细胞癌(P<0.05)。结论:皮肤肿瘤中存在iNOS的表达,其合成的一氧化氮可能在皮肤的癌前病变及恶性肿瘤的发生、发展中起到一定的作用。其表达可能有助于皮肤肿瘤恶性度及预后的判断。     

Ber EP4与EMA染色在皮肤基底细胞上皮瘤和鳞状细胞癌诊断中的意义

目的 观察BerEP4和EMA染色在皮肤基底细胞上皮瘤和鳞状细胞癌诊断中的意义.方法 用免疫组化SP法检测BerEP4和EMA在皮肤基底细胞上皮瘤、鳞状细胞癌、光线性角化病、Bowen病、脂溢性角化病、寻常疣和基底鳞状细胞癌皮损肿瘤成分及周围组织、皮肤附属腺体中的表达.结果 所有基底细胞上皮瘤和基底鳞状细胞癌肿瘤细胞呈BerEP4阳性,而鳞状细胞癌、光线性角化病、Bowen病、脂溢性角化病和寻常疣呈BerEP4阴性;多数鳞状细胞癌、Bowen病和部分光线性角化病肿瘤细胞及病变区域呈EMA阳性,而基底细胞上皮瘤、基底鳞状细胞癌、脂溢性角化病和寻常疣呈EMA阴性.结论 联合使用BerEP4和EMA能很好地协助诊断皮肤基底细胞上皮瘤、基底鳞状细胞癌、癌前病变及一些良性增生性皮肤病.     

桥粒芯糖蛋白1在不同表皮肿瘤中表达的研究

目的：了解桥粒芯糖蛋白1与表皮肿瘤的病理及生物学行为之间的关系。方法：采用过氧化物酶标记的链霉卵白素免疫组织化学染色方法，检测了桥粒芯糖蛋白1(Dsgl)在鳞状细胞癌、基底细胞癌、Bowen病、日光角化病、角化棘皮瘤、脂溢性角化病及正常皮肤中的表达。结果：Dsgl在正常表皮中显著表达；在鳞状细胞癌和基底细胞癌的肿瘤组织中表达显著减弱或消失；在Bowen病和日光角化病细胞间变区域无表达；在绝大多数角化棘皮瘤、脂溢性角化病中的表达为强而连续的胞膜染色，与正常表皮中的表达相似。结论：皮肤恶性肿瘤中Dsgl的表达显著减弱或消失，可能与肿瘤的侵袭性和转移有关，Dsgl可能对表皮良、恶性肿瘤的鉴别诊断具有一定价值。     

桥粒芯糖蛋白1和2在不同表皮肿瘤中的表达

目的 探讨桥粒相关蛋白与皮肤肿瘤的关系,对桥粒芯糖蛋白1和2在鳞状细胞癌、日光性角化病、角化棘皮瘤、脂溢性角化病中的表达水平进行了比较研究.方法 免疫组化染色方法.结果 桥粒芯糖蛋白1和2在正常皮肤表皮全层细胞间呈现较强的染色,鳞状细胞癌组织中表达显着减弱或完全无表达,日光性角化病表皮正常区域表达正常或下调,细胞间变区域无染色,角化棘皮瘤和脂溢性角化病表皮中表达水平与正常皮肤的表达非常近似.结论 桥粒芯糖蛋白1和2在恶性皮肤癌中表达下调,可能与皮肤肿瘤的侵袭和转移有关.     

MIC-1和uPA蛋白在皮肤鳞状细胞癌组织中的表达及与组织学分级和发病部位的关系

目的 探讨MIC-1和uPA蛋白在皮肤鳞状细胞癌中的表达及与组织学分级和发病部位的关系。方法 应用免疫组化SP法检测42例皮肤鳞状细胞癌组织及42例正常对照皮肤中MIC-1及uPA蛋白的表达,并分析其与组织学分级及发病部位的关系。结果 皮肤鳞状细胞癌组织中MIC-1(66.67%)及uPA蛋白(78.57%)阳性表达率均显著高于正常对照皮肤组织中的阳性表达率(16.67%和28.57%),差异均有统计学意义(P均<0.05);皮肤鳞状细胞癌组织中MIC-1及uPA蛋白阳性表达率均与鳞状细胞癌病理组织学分级密切相关(P均<0.05);MIC-1与uPA蛋白的表达呈正相关(P<0.05)。结论 皮肤鳞状细胞癌组织中MIC-1和uPA蛋白的表达均显著升高,其高表达可能与皮肤鳞状细胞癌发生和发展有关。     

皮肤良、恶性增殖性疾病中△Np63的检测

目的观察△Np63在皮肤良、恶性增殖性疾病中的表达,并探讨其意义。方法应用免疫组化SP法检测30例脂溢性角化症、30例日光性角化病、30例基底细胞癌及10例正常皮肤组织中△Np63的表达,并采用Image-Pro Plus6.0(IPP)图像分析软件定量测定每个视野中阳性表达的平均光密度值。结果△Np63在脂溢性角化症组表达的平均光密度为0.0391±0.0169,日光性角化病组为0.0262±0.0184;基底细胞癌组为0.0498±0.0222;正常皮肤组为0.0056±0.0019。△Np63在各组的阳性表达差异有统计学意义(P<0.05),它除在脂溢性角化症及基底细胞癌组的表达差异无统计学意义(P>0.05)外,余组内两两比较的差异也均有统计学意义(P均<0.05);但是它在不同部位的脂溢性角化症、日光性角化病和基底细胞癌中的表达差异均无统计学意义(P均>0.05)。结论再次印证了△Np63是未分化上皮来源肿瘤的标记物。     

水通道蛋白3在四种皮肤肿瘤中的表达

目的 探讨水通道蛋白3（AQP3）在四种皮肤肿瘤组织中的表达及意义。方法 应用免疫组织化学方法检测30例脂溢性角化病、15例Bowen病、32例鳞状细胞癌、17例恶性黑素瘤及15例正常人皮肤组织中AQP3的表达。结果 脂溢性角化病、Bowen病、鳞状细胞癌、恶性黑素瘤及正常人表皮组织中均存在AQP3蛋白的表达;脂溢性角化病皮损中AQP3表达水平与正常人对照组差异无统计学意义（P > 0.05）;Bowen病、鳞状细胞癌及恶性黑素瘤皮损中AQP3蛋白表达显著高于正常人对照组（P < 0.01）,其中鳞状细胞癌与恶性黑素瘤的表达最强,均显著高于Bowen病（P < 0.01）,但鳞状细胞癌与恶性黑素瘤比较差异无统计学意义（P > 0.05）。此外,在鳞状细胞癌中AQP3的表达与肿瘤的分化有显著相关性（P < 0.01）;在已转移恶性黑素瘤中AQP3的表达显著高于未转移恶性黑素瘤（P < 0.05）。结论 AQP3在皮肤恶性肿瘤中表达上调。     

端粒酶逆转录酶在皮肤肿瘤原位表达水平的比较

目的　研究端粒酶在皮肤恶性肿瘤发病机制中的作用。方法　采用人端粒酶逆转录酶 (hTERT)cRNA探针与石蜡标本进行原位杂交的方法检测 3 0例皮肤基底细胞癌、15例皮肤鳞状细胞癌、19例脂溢性角化、14例正常皮肤中hTERTmRNA的表达水平 ,并进行比较。结果　hTERT阳性率基底细胞癌为 73 .3 5 %(2 2 /3 0 ) ,鳞状细胞癌为80 .0 0 %(12 /15 ) ,均明显高于脂溢性角化 3 6.84%(7/19)和正常皮肤 2 8.5 7%(4 /14 ) ,并具有统计学意义。结论　hTERT在恶性皮肤肿瘤中的阳性表达率明显高于良性肿瘤和正常皮肤 ,提示端粒酶在皮肤恶性肿瘤发病机制中起着重要作用。原位杂交检测hTERT表达水平的方法有可能成为鉴别皮肤良恶性肿瘤的辅助检查手段。     

疣状表皮发育不良并发鳞状细胞癌

报告1例表现为脂溢性角化病样皮损的疣状表皮发育不良并发鳞状细胞癌.患者男,52 岁.四肢皮肤丘疹、斑块20余年,右手背溃疡2 个月.右前臂斑块组织病理检查:同时有疣状表皮发育不良及脂溢性角化病的表现.右手背溃疡组织病理表现符合高分化鳞状细胞癌.     

CXCR7在常见皮肤恶性肿瘤及其细胞株中的表达及意义

目的 探讨趋化因子受体CXCR7在皮肤鳞状细胞癌、基底细胞癌、侵袭性皮肤黑素瘤及其细胞株中的表达及其意义。方法 收集30例皮肤鳞状细胞癌、25例基底细胞癌、30例皮肤黑素瘤的癌组织,采用免疫组织化学方法,检测CXCR7蛋白表达水平。采用RT-PCR、细胞免疫组化方法检测CXCR7在A375、M14、A431、HaCaT细胞株中mRNA及蛋白水平。结果 CXCR7在侵袭性皮肤黑素瘤中表达明显,高表达率为80%（24/30）,皮肤鳞状细胞癌及基底细胞癌分别为26.67%（8/30）、8%（2/25）;皮肤黑素瘤CXCR7高表达率与鳞状细胞癌、基底细胞癌比较,差异均有统计学意义（χ2值分别为17.16和28.36,P值均 < 0.05）。CXCR7 mRNA在A375、M14、A431细胞株中均可检出,其中A375表达最强,而HaCaT细胞不表达;细胞免疫组化显示,仅在A375细胞见棕黄色颗粒着色。结论 皮肤黑素瘤及其细胞株A375高表达CXCR7,其可能参与了其恶性侵袭与转移。     

p53, cyclin-D1, PCNA, AgNOR expression in squamous cell cancer of the lip: a multicenter study

BACKGROUND: The development of squamous cell carcinoma of the lower lip is an interesting model of photocarcinogenesis because of the structural and topographic characteristics of the lips. The purpose of this study was to evaluate the expression of immunohistochemical markers on the lips of patients with lower lip squamous cell carcinoma (LLSCC), compared with a control population. METHODS: Of the 98 subjects involved in the study, 58 were suffering from squamous cell carcinoma of the lower lip. The remaining 40 acted as a control. The case studies were taken from six university and hospital dermatology and plastic surgery departments. Questionnaires were administered to assess the risk factors for LLSCC. The cases involving squamous cell carcinoma underwent surgical excision and punch biopsy specimens were obtained from 20 control patients. Tissues were prepared in 5-microm-thick sections to carry out the following immunohistochemical study: PCNA, p53, AgNOR, cyclin-D1, bcl-2. RESULTS: The lower lip was the predominant location of squamous cell carcinoma, with the following factors playing important roles: chronic sun exposure, history of smoking, alcohol use and familial risk of cutaneous tumors. The male/female ratio in our survey was 5:1. The p53 protein was positive in approximately 50% of SCC cases and in 20% of controls. This protein is mostly associated with chronically photoexposed skin areas. AgNOR positivity increased with the loss of cellular differentiation; a progressive increase in size and a poorly defined shape were evident in poorly differentiated carcinomas. CONCLUSIONS: The results of this multicenter study showed that there is a noticeable difference in the expression of PCNA, p53, cyclin-D1, and AgNOR in tissues from patients with LLSCC and controls.     

Immunohistochemical localization of proliferating cell nuclear antigen/cyclin in human skin

Summary Expression of proliferating cell nuclear antigen/cyclin (PCNA/cyclin) in skin tissue specimens and cultured keratinocytes was studied using a monospecific antibody, obtained from a patient with systemic lupus erythematosus, and a monoclonal antibody. Indirect immunofluorescent staining revealed that cultured keratinocytes obtained from human foreskins expressed PCNA/cyclin as variable nuclear patterns in 15–30% of the cells. In normal human skin tissue specimens, PCNA/cyclin was demonstrated in only a few basal cells. Interestingly, PCNA/cyclin was expressed strongly in almost all the cells of the lowest layer of the epidermis adjacent to squamous cell carcinomas, whereas the tumor aggregates themselves had no positive staining. In contrast, no such characteristic staining was demonstrated in specimens of basal cell carcinoma. The staining pattern of PCNA/cyclin was different from that of Ki-67 in the skin tissue specimens. Our results suggest that PCNA/cyclin could be a useful marker of cell proliferation.     

Cutaneous squamous cell carcinomas and papillomaviruses in renal transplant recipients: a clinical and molecular biological study.

Papillomaviruses are strongly implicated in squamous cell carcinomas arising on mucosal surfaces of normal individuals, and in the skin carcinomas of epidermodysplasia verruciformis suffers. Renal transplant recipients often have numerous skin warts and, in Australia particularly, a very high risk of developing cutaneous squamous cell carcinoma. To determine the magnitude of this risk, and to test whether papillomaviruses are specifically associated with these cancers, we examined 188 renal transplant recipients for skin cancers and tested 235 biopsy specimens of (histologically proven) squamous cell carcinomas for the presence of viral DNA. The risk of developing squamous cell carcinoma increased with duration of transplant: the probability being 25% after 9.5 years (standard error = 1.3 years) rising to 50% at 20.6 years (standard error 6.8 years). Factors which did not appear to affect the risk of tumour development included the patients sex and their skin type. However the age at transplant significantly altered the risk with patients transplanted at greater than 35 years developing tumours about four times more rapidly than patients less than or equal to 35 years. Extensive hybridisation tests for the presence of papillomavirus DNA in squamous cell carcinomas were negative, as was the polymerase chain reaction amplification method using general L1 gene oligonucleotide primers. Our data do not support a role for papillomavirus in the maintenance of cutaneous squamous cell carcinoma.     

CD44v6和PCNA在皮肤鳞状细胞癌中的表达及其临床意义

目的 :　研究CD4 4v6和PCNA与皮肤鳞状细胞癌 (SCC)临床病理特征的关系。方法 :　免疫组化法研究 4 8例SCC原发灶、11例淋巴结转移灶和 10例正常皮肤组织中CD4 4v6和PCNA的蛋白表达。结果 :　SCC标本中 ,CD4 4v6表达下调 (P <0 .0 1) ,分化越差下调越明显 (P <0 .0 5 ) ;PCNA表达增高 (P <0 .0 5 ) ,分化越差增高越明显 (P <0 .0 1)。二者与临床分期、淋巴结转移及发病部位均无关 (P >0 .0 5 ) ,且CD4 4v6和PCNA的表达无相关性 (r=- 0 .176 ,P >0 .0 5 )。结论 :　CD4 4v6和PCNA均可作为研究SCC发生与发展的独立的生物学指标     

鲍温病和皮肤鳞状细胞癌皮损中ΔNp63的表达

目的观察ΔNp63在鲍温病和皮肤鳞状细胞癌中的表达情况。方法应用免疫组化Envision法检测10例正常皮肤、30例鲍温病及30例皮肤鳞状细胞癌组织中ΔNp63的表达水平,并对该3组标本ΔNp63的表达水平进行比较。结果在鲍温病的皮损组织中,ΔNp63主要在表皮全层细胞中弥漫性表达;在皮肤鳞状细胞癌中,ΔNp63表达与其分化程度相关(P=0.004),即在高分化鳞状细胞癌中,ΔNp63在癌巢外周基底样细胞表达,在中分化鳞状细胞癌中,ΔNp63在癌巢中有弱弥漫性表达。ΔNp63在鲍温病、皮肤鳞状细胞癌及正常皮肤中的阳性表达率差异有统计学意义(P<0.05);但不同部位的鲍温病和皮肤SCC组组织中,ΔNp63表达差异均无统计学意义(P均>0.05)。结论ΔNp63多考虑是未分化及低分化上皮来源肿瘤的标记物。     

Caspase-3在皮肤鳞状细胞癌及光线性角化病中的表达

目的：检测Caspase-3在皮肤鳞状细胞癌及光线性角化病组织中的表达。方法： 应用免疫组化法检测16例皮肤鳞状细胞癌皮损、27例光线性角化病皮损及24例正常皮肤组织中Caspase-3蛋白的表达。结果：Caspase-3在皮肤鳞状细胞癌、光线性角化病及正常皮肤组织的表达率分别为37.50%,51.85%,79.17%,其表达含量在皮肤鳞状细胞癌、光线性角化病、正常皮肤组织逐渐增加。结论：Caspase-3蛋白表达下调可能参与皮肤鳞状细胞癌及光线性角化病的发病过程。     

Jagged1蛋白在银屑病、基底细胞癌及皮肤鳞状细胞癌中的表达

目的探讨Jagged1蛋白在银屑病、基底细胞癌及皮肤鳞状细胞癌中的表达及意义。方法采用免疫组化Envision法检测Jagged1蛋白在银屑病、基底细胞癌及皮肤鳞状细胞癌皮损中的表达。结果 Jagged1蛋白在寻常性银屑病患者皮损中呈阴性表达,在基底细胞癌及皮肤鳞状细胞癌中的表达较正常人皮肤增强,差异有统计学意义(P<0.01);Jagged1蛋白在基底细胞癌及皮肤鳞状细胞癌中的表达较银屑病增强,差异有统计学意义(P<0.05)。结论 Jagged1蛋白在银屑病发病机制中与角质形成细胞异常增生及真皮乳头血管增生等组织病理变化可能不相关,提示此蛋白可能与皮肤恶性肿瘤的异常增生有关。     

Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: a clinicopathologic and immunohistochemical study of 6 patients

We report 6 cases of pseudoepitheliomatous hyperplasia (PEH) mimicking squamous cell carcinoma in association with an atypical CD30+ dermal infiltrate. Three patients had lymphomatoid papulosis type A, and 3 patients had cutaneous CD30+ lymphoma. All 6 cases showed histologic evidence of PEH with keratinocyte atypia. In 4 cases there was significant atypia to prompt a diagnosis of squamous cell carcinoma. Three of these received treatment with wide local excision and 2 had been engrafted. Immunohistochemical staining for epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha) showed similar expression in lesional and perilesional skin. Epidermal growth factor receptor (EGFR) expression by the proliferating epithelium was similar to that of the suprabasal adjacent normal epidermis. There was no aberrant expression of EGF, TGF-alpha, and EGFR by atypical lymphocytes. These cases demonstrate that PEH associated with CD30+ lymphoproliferative disease may closely resemble squamous cell carcinoma, thereby leading to inappropriate diagnosis and treatment.     

Expression of minichromosome maintenance 5 protein in proliferative and malignant skin diseases

BACKGROUND: The entire minichromosome maintenance (MCM) family (MCM2-7) play roles in the initiation and elongation of DNA replication. Many studies have demonstrated that MCM proteins may be better indicators of a wide variety of proliferative or cancer cells in malignant tissues. OBJECTIVES: To characterize the pattern and frequency of MCM5 expression in proliferative and malignant skin diseases in comparison with those of proliferating cell nuclear antigen (PCNA). METHODS: Twelve normal skin specimens, 12 specimens of psoriasis, 21 specimens of bowenoid papulosis (BP), 16 specimens of Bowen's disease (BD), 38 specimens of skin squamous cell carcinoma (SCC), and 11 specimens of basal cell carcinoma (BCC) were subjected to immunohistochemical staining for MCM5 and PCNA. Results MCM5 protein was expressed in the lower layers of epidermis in psoriasis, while MCM5 protein were present throughout the tumor cells in BP, BD, and moderately/poorly differentiated SCC. MCM5 protein was preferentially expressed in the periphery of well-differentiated SCC or bigger nests of BCC, although some small nests of BCC seemingly showed diffuse staining patterns. The percentages of MCM5-positive cells were 15.7% in normal skin, 21.8% in psoriasis, 75.9% in BP, 83.8% in BD, 63.5% in well-differentiated SCC, 77.5% in moderately differentiated SCC, 79.8% in poorly differentiated SCC, and 21.2% in BCC in average. Well-differentiated SCC showed a significantly lower percentage of positive cells than did moderately differentiated SCC or poorly differentiated SCC. MCM5 staining basically show a similar staining pattern to that of PCNA, but more cells tended to be stained with MCM5 than with PCNA. CONCLUSIONS: Our results demonstrate pattern and frequency of MCM5 expression in various skin diseases and suggest that MCM5 may be a useful marker to detect cell proliferation in skin tissue sections.